Building a Stronger Clinical Trials Industry Post-Pandemic: Modal-Guided Design | Technology Networks

The focus on COVID-19 has caused many trials to be delayed, canceled or scaled back – meaning that the development of new medicines for patients in other areas has been slowed. At the same time, it has exposed pre-existing flaws in the industry. To recover from the pandemic, the industry must now address these underlying issues.